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Summary
A live attenuated vaccine (Zostavax®) 
against herpes zoster (HZ) and posther-
petic neuralgia (PHN) was licensed for 
persons 50 years of age and older in 2006 
and became available in Germany in Sep-
tember 2013. Based on the conclusion, 
that an effective and sustainable reduc-
tion of the HZ disease burden cannot be 
achieved with this vaccine, the STIKO 
decided against issuing a recommenda-
tion for routine HZ vaccination at this 
time. This decision is based on a system-
atic review of available data on the effica-
cy, duration of protection, and safety of 
the vaccine, and is supported by the re-
sults of health economic modelling. Both, 
the risk of developing HZ and the severity 
of the illness increase markedly with age. 
The efficacy of the vaccine, however, de-
creases with advancing age, from 70% for 
persons in their 50s to 41% for persons in 
their 70s to less than 20% for persons 80 
years of age and older. The duration of vac-
cine related protection is limited to only 
a few years. The modelling results show 
only a slight, age-dependent reduction in 
the total number of HZ cases through vac-
cination with the live attenuated vaccine. 
The reduction ranged from 2.6% for per-
sons vaccinated at the age of 50 to 0.6% 
for those vaccinated at the age of 80, based 
on assumed vaccine coverage of 35.5%. In 
addition to the vaccine’s poor efficacy and 
duration of protection, HZ vaccination 
does not offer any added value in terms of 
herd immunity, since HZ is a disease of an 
endogenously reactivated pathogen with 
low transmission potential. 
Finally, the live attenuated vaccine is 
often contraindicated in persons who are 
at greatest risk of HZ and its complica-
tions. Thus, in the overall appraisal, the 
epidemiological benefit-risk assessment 
of the HZ vaccination did not lead to a 
recommendation for routine vaccination 
with the live attenuated vaccine. An indi-
vidual benefit-risk assessment may, how-
ever, lead to a different decision in indi-
vidual patients.
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1. Introduction
In Germany, more than 300,000 persons 
over the age of 50 develop HZ every year 
[1]. HZ is caused by a reactivation of the 
varicella zoster virus (VZV) that remained 
latent in sensory ganglia after the prima-
ry infection. The primary VZV infection 
causes chicken pox, and usually occurs 
years to decades earlier. About 6–18% of 
HZ cases develop a postherpetic neuralgia 
(PHN) as the most frequent HZ compli-
cation [1]. The symptom of this is chron-
ic pain that lasts months or years and sig-
nificantly reduces quality of life. In May 
2006, the European regulatory authori-
ty (European Medicines Agency, EMA) 
approved a live attenuated vaccine (Zos-
tavax®; Merck) for the prevention of HZ 
and the PHN it causes for persons age 50 
and over. This background paper sum-
marizes the data basis the STIKO used to 
reach its decision on standard vaccination 
with the live attenuated vaccine. Based on 
the STIKO standard operating procedure 
(SOP) for the systematic development of 
vaccination recommendations, the dis-
ease burden of HZ in Germany was ascer-
tained, systematic reviews of the efficacy 
and safety of the vaccine were conducted, 
and the data on the duration of protection 
of the vaccine evaluated. The potential ep-
idemiological impact of a vaccination was 
modelled for different age groups, taking 
HZ epidemiology in Germany and oth-
er vaccine-specific input parameters into 
account. Based on this model, a health 
economics evaluation of the vaccination 
was conducted. This background paper 
includes an extensive appendix contain-
ing further information on the system-
atic reviews conducted. The appendix is 
available online as Electronic Supplemen-
tary Material (ESM_STIKO_Herpes_zos-
ter_2017.pdf). Studies on the HZ sub unit 
vaccine Shingrix® (GSK), currently in li-
censing process, were identified during 
the data processing. Since this vaccine is 
not approved yet, the STIKO did not take 
it into consideration for this decision. 
2. Pathogenesis and clinical 
features of HZ
HZ, also known as shingles, is caused by 
a reactivation of the latent VZV infection. 
The clinical manifestation of this illness is 
normally a blister-like rash on one side, 
which is characteristically limited to one 
single dermatome or a few adjacent der-
matomes. The illness is commonly ac-
companied by radicular radiating pain 
along the dermatomes affected. Patients 
frequently suffer significant pain that can 
last weeks to months, in some cases even 
years, and that considerably restricts qual-
ity of life [2–4].
2.1. Aetiology
VZV, an enveloped virus with dou-
ble-stranded DNA from the family of 
human herpes viruses (HHV 3), causes 
varicella (chicken pox) in the primary in-
fection. This highly contagious disease is 
transmitted through airborne droplets, or 
as a smear infection through chickenpox 
blisters [5]. Varicella-zoster virus sero-
prevalence in Germany was very high be-
fore the general varicella vaccination rec-
ommendation was issued in 2004: over 
95% of people 14 years of age and older 
exhibited IgG antibodies to VZV [6, 7].
VZV persists latently after the prima-
ry exogenous infection (varicella) in the 
neurons of sensory spinal ganglia or the 
nerves of the brain [8]. In general, the la-
tency phase lasts for several decades be-
fore the productive infection is reactivated 
and HZ occurs. HZ normally occurs only 
once, but second and third HZ episodes 
are possible and do happen occasionally. 
The frequency of repeated HZ increases 
with time after the first HZ illness in per-
sons with a healthy immune system from 
1.7% (95% CI 1.0–2.3) after 2 years to 
3.2% (95% CI 2.3–4.2) after 4 years, then 
to 4.4% (95% CI 3.3–5.4) after 6 years and 
5.7% (95% CI 4.4–6.9) after 8 years [9]. 
VZV replication can be reactivated, lead-
ing to HZ disease, in particular in cases 
of waning T-cell-specific immunity (e. g. 
with advancing age or on immunosup-
pressive therapy, see also risk factors), 
but also spontaneously in immunocom-
petent persons and in young adults, chil-
dren, and adolescents [10]. HZ can occur 
only in persons who have previously had 
a primary VZV infection, including those 
who have been vaccinated with a live VZV 
vaccine. But the frequency of reactivation 
of the vaccine virus is significantly lower 
than that of the wild virus [11]. HZ is far 
less contagious than varicella: only 20% 
of persons susceptible to VZV developed 
chicken pox following contact to a HZ 
case in the household, whereas the rate of 
secondary varicella infections ranges from 
61% to 100% after household contact to a 
varicella case [5]. Virus transmission oc-
curs until lesons are crusted through aer-
osols or through smear infection with the 
contents of the blisters, and can be further 
reduced by covering the skin lesions [12].
2.2. Symptoms
VZV reactivation leads to inflammation of 
the sensitive spinal ganglia affected. Typ-
ically the virus spreads along the senso-
ry nerves to the skin, where it causes the 
characteristic presentation of painful der-
matomal HZ with erythema and clusters 
of papulovesicular, later papulous efflores-
cences. But it can also remain limited to 
the nerves, causing radicular pain in the 
absence of skin lesions (zoster sine her-
pete; [13]). Normally only one side of the 
body is affected by the zoster exanthem. 
[14]. In 70–80% of HZ cases, a promod-
al stage of 3–5 days precedes the disease, 
with varying symptoms [15]. Patients re-
port general symptoms such as fever, fa-
tigue, and exhaustion, as well as burning, 
paresthesia, or pain that is limited to the 
dermatome affected. After the skin lesions 
have healed and the acute pain symptoms 
have improved, chronic pain and allody-
nia, also described as postherpetic neural-
gia (PHN), are observed [16]. 
2.3. Localization
The area served by the affected nerves de-
termines the localization of HZ. Any der-
matome can be affected. HZ occurs most 
frequently as zoster thoracicus in the area 
of the thoracic dermatomes and as zoster 
capitis in the head region. Around 50% to 
56% of cases affect the thoracic dermat-
omes, and 20% the brain nerves [17, 18]. 
Less frequently affected, in descending 
order, are the cervical, lumbar, and sacral 
segments. If the trigeminal nerve is affect-
ed, zoster ophthalmicus can occur. It nor-
mally affects one eye, and can lead to vi-
sion loss or total blindness. Other zoster 
manifestations in the area of the trigem-
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inal nerve are zoster maxillaris und zos-
ter mandibularis. Zoster oticus and VZV 
vasculitis can manifest in the head region 
[8]. If the virus disseminates through the 
blood, it leads to a systemic syndrome 
(zoster disseminatus) that occurs very 
rarely in immunocompetent persons, but 
more frequently in persons with compro-
mised immune systems [19, 20].
2.4. Complications
PHN is the most common complication 
of zoster. It is characterized by severe pain, 
often described as burning, and the allo-
dynia that occurs or persists after acute 
skin symptoms fully abate [21, 22]. The 
risk of developing PHN increases with 
age. From a pathophysiological perspec-
tive, it seems this is due to inflammatory 
nerve damage involving the destruction 
of peripheral nerve structures and of neu-
rons in the sensory ganglia [23]. Various 
definitions of PHN are used in scientific 
literature, taking varying durations of pain 
symptoms after the initial rash into ac-
count. PHN can last for weeks or months, 
and sometimes for many years [8, 24]. 
Other complications of HZ are acute 
or sustained damage to the eye caused 
by zoster ophthalmicus, bacterial super-
infections of the skin lesions caused by 
staphylococcus or streptococcus infec-
tions (zoster gangraenosus), palsy of the 
brain and peripheral nerves, zoster men-
ingitis, zoster encephalitis, zoster myelitis, 
zoster vasculitis with neurological damage 
including stroke, and visceral dissemina-
tion involving the internal organs (pneu-
monia, oesophagitis, myocarditis, entero-
colitis, pancreatitis). 
Immunocompromised persons or pa-
tients on immunosuppressive therapy are 
at greater risk of experiencing complica-
tions. The rash often covers a larger area 
and lasts longer [25]. The risk of dissemi-
nated HZ is also elevated in persons with 
immunosuppression [26].
2.5. Risk factors
Persons with pronounced immunosup-
pression, e. g. patients with cancer or HIV, 
persons who have had an organ or bone 
marrow transplant, and patients on im-
munosuppressive therapy, have the high-
est risk of developing HZ [27]. Diseases 
that are associated with a slightly elevated 
HZ risk include rheumatoid arthritis, sys-
temic lupus erythematosus, inflammatory 
bowel disease, chronic obstructive pulmo-
nary disease, asthma, chronic kidney dis-
ease, and type-1 diabetes [27].
3. Epidemiology
The incidence for HZ is approximately 6 
cases per 1,000 German population annu-
ally [28]. The incidence is higher among 
women than among men, and rises con-
tinuously from around the age of 50 years 
[28–30]. Based on statutory health in-
surance (SHI) data, the age-specific in-
cidence of HZ ranges from 4 cases per 
1,000 person-years (PY) among persons 
under the age of 50 to 14 cases per 1,000 
PY among 80–89-year-olds [29]. Claims 
data from the associations of statutory 
health insurance physicians reveal simi-
lar findings, with the incidence of HZ at 
6.2/1,000 PY among 50–54-year-olds ris-
ing to 13.2/1,000 PY among those 90 years 
of age and older [28]. Evaluations of hospi-
talization data also demonstrate a rise with 
increasing age from approx. 6.7/100,000 
inhabitants between 20 and 49 years of 
age to 57.7/100,000 inhabitants 70 years 
of age and older (average of years 1995 to 
2012; [30]). These data also show a con-
tinuous rise in age-adjusted hospitaliza-
tions from 9/100,000 inhabitants in 1995 
to 17/100,000 in 2012. 
The HZ incidence in persons with im-
munosuppression was around twice as 
high as in immunocompetent persons (12 
vs. 6/1,000 PY; [29]).
HZ-related mortality appears to be 
low. According to causes of death statis-
tics (link to www.gbe-bund.de), the medi-
an annual number of deaths among per-
sons at age 50 and over caused by HZ was 
around 75 between the years 2005 and 
2014. Claims data from the association of 
statutory health insurance physicians con-
firm the low mortality of 0.21 per 100,000 
inhabitants aged ≥50 years [28]. Accord-
ing to that data, mortality exceeding one 
death caused by HZ per 100,000 inhabit-
ants does not occur until the age of >85 
years.
The most frequent complications (be-
sides PHN) are further involvement of the 
nervous system (15.5% of cases), zoster 
ophthalmicus (4.8%), disseminated zos-
ter (0.6%), zoster encephalitis (0.4%), and 
zoster meningitis (0.1%). A total of ap-
prox. 28% of HZ cases led to one or more 
complications [29]. The risk of complicat-
ed disease progression increased with age, 
and was slightly higher among persons 
with immunosuppression than among 
immunocompetent persons with HZ. 
4. Live attenuated herpes zoster 
vaccine
A live attenuated HZ vaccine, Zostavax® 
(manufacturer: Merck Sharp & Dohme; 
market authorization holder (until 
31. 12. 2016): Sanofi Pasteur MSD), was 
licensed for Europe on 19 May 2006 by 
the European Medicines Agency (EMA; 
[31]). The initial registration in 2006 ap-
plied to the deep-frozen formulation; the 
lyophilized formulation was approved in 
January 2007. The lyophilized formula-
tion of the vaccine has been available in 
Germany since September 2013. One dose 
(0.65 ml) of the reconstituted live HZ vac-
cine (powder plus solvent for the recon-
stitution to a suspension) contains at least 
19,400 plaque-forming units (PFU) of the 
attenuated varicella zoster virus of the 
Oka/Merck strain. Additional ingredients 
in the vaccine are: saccharose, hydrolyz-
ed gelatine, sodium chloride, potassium 
dihydrogen orthophosphate, potassium 
chloride, sodium L-glutamate monohy-
drate, disodium hydrogen phosphate, 
sodium hydroxide (for pH adjustment), 
and urea. The vaccine does not contain 
any thimerosal or other preservatives. 
The Oka strain, which is also contained 
in varicella vaccines for the prevention of 
chicken pox, was isolated in Japan in the 
1970s from samples taken from a three-
year-old boy who was ill with chicken pox 
[32]. The virus concentration is different 
in the vaccines. It is 14 times higher in the 
HZ vaccine than in the varicella vaccine 
[32]. The strain was attenuated through 
repeated cultivation in human embryon-
ic lung cells, then passaged in embryonic 
guinea pig embryo fibroblasts. The virus 
is cultivated in human diploid cells [33]. 
The HZ vaccine is approved for the pre-
vention of HZ and PHN caused by HZ 
with a single dose in persons age 50 and 
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over. The necessity and timing of a boost-
er dose have not yet been determined. The 
vaccine can be administered as a subcu-
taneous (s. c.) or intramuscular (i. m.) in-
jection. It should be administered s. c. in 
patients with severe thrombocytopenia or 
coagulopathy. 
The vaccine is contraindicated for per-
sons with congenital or acquired immu-
nodeficiency (e. g. resulting from acute or 
chronic leukemia, lymphoma, other bone 
marrow or lymphatic diseases, or HIV/
AIDS), on immunosuppressive therapy 
(including high doses of corticosteroids), 
with active, untreated tuberculosis, who 
are pregnant, or who have known hyper-
sensitivity to ingredients in the vaccine. 
The vaccine can be administered simulta-
neously with an inactivated influenza vac-
cine to different body sites. The live HZ 
vaccine and the 23-valent pneumococ-
ci polysaccharide vaccine Pneumovax® 
must not be administered simultaneous-
ly, as this would negatively impact the im-
munogenicity of the live HZ vaccine. No 
data are available on the simultaneous ad-
ministration with other vaccines.
5. Goal of vaccination
The STIKO has defined the reduction of 
HZ illnesses, their complications, and the 
long-term consequences caused by HZ 
in persons ≥50 as the primary goal of the 
vaccination. This aim should be specified 
according to other age groups, taking the 
results of the systematic review on vac-
cine efficacy, the duration of vaccine in-
duced protection for different age groups, 
and the results of the modelling and the 
health economics evaluation into account. 
6. Method of searching and 
assessing the quality of evidence
A working group of the STIKO pro-
cessed the evidence on efficacy and safe-
ty of the live zoster vaccine and assessed 
the quality of the evidence according to 
the STIKO standard operating procedure 
(SOP) for the systematic development of 
evidence-based recommendations on im-
munization [34]. After the STIKO formu-
lated the primary goal of the HZ vaccina-
tion, and following the GRADE (Grading 
of Recommendations Assessment, De-
velopment and Evaluation) methodolo-
gy, patient-relevant outcomes of the HZ 
vaccination were defined and classified 
according to their importance for de-
cision-making. The outcomes were as-
sessed on a scale of 1–9 as essential/crit-
ical (7–9 points), important (4–6 points), 
or of limited significance (1–3 points) for 
the decision by the working group mem-
bers (. Table 1). 
In order to identify clinical studies 
on vaccine safety and efficacy, the sys-
tematic literature research was carried 
out in accordance with the requirements 
of the PRISMA statement (preferred re-
porting items for systematic reviews and 
meta-analyses). The following databas-
es were searched taking patient-rele-
vant outcomes into account: MEDLINE; 
EMBASE, BIOSIS Preview, SciSearch, 
Cochrane Central Register of Controlled 
Trials, Cochrane Database of Systematic 
Reviews, GLOBAL Health [35]. The com-
plete search strategies, flowcharts, and in-
clusion and exclusion criteria are shown 
in the appendix (ESM_STIKO_Herpes_
zoster_2017.pdf). Additionally, the refer-
ence lists of the studies included and the 
reviews identified were screened for oth-
er potentially relevant studies. No limita-
tions were placed on publication status or 
language. 
The literature research and data extrac-
tion were conducted by two independent 
investigators. The relevant study charac-
teristics of the original studies that ful-
filled the inclusion criteria were recorded 
using a standardized extraction form, and 
their internal and external validity were 
evaluated. Discrepancies between the two 
investigators were discussed until they 
reached consensus. 
The data extracted on patient-relevant 
endpoints from the studies included were 
entered into the review management soft-
ware RevMan (version 5.2), and the rel-
ative risk (RR) and corresponding 95% 
confidence intervals (95% CI) of the vac-
cine group compared to the placebo group 
were calculated for the relevant outcome. 
If more than one study was available, a 
meta-analysis was conducted in which 
individual results were summarized into 
an overall result and the pooled point es-
timates determined. If heterogeneity was 
present (assessed using I² statistics), a ran-
dom effects model was used, otherwise the 
data were summarized using a fixed-ef-
Table 1 Hierarchy of patient-relevant outcomes for the evaluation of the efficacy and safety of the live attenuated herpes zoster vaccine
Focus of the 
systematic review
Population Intervention Comparator Outcomes Assessment of the sig-
nificance of outcomes 
for a decision#
Efficacy Adults ≥50y;
(or other age groups)1
Vaccination 








Other complications (incl. death) 9
Hospitalization 7
Safety Adults ≥50y;
(or other age groups)1
Vaccination 






Local reactions, not serious 3
Severe local reactions 7
Systemic reactions, not serious 4
Severe systemic reactions 7
Scale from 1–9: “critical” (7–9 points), “important” (4–6 points), or “of limited significance” (1–3 points). Each endpoint is to be assessed on its own. The same score can be 
assigned to multiple endpoints, as different endpoints can be equally significant.
1Age group should be selected according to the modelling results
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fects model. Using the RR, the formula 
([1-RR]*100) was applied to calculate the 
vaccine efficacy or effectiveness, or the risk 
of adverse side effects of the vaccination.
To compile the GRADE evidence pro-
file, data from the outcomes defined as 
“critical” and “important” were entered 
into the GRADEprofiler (version 3.6) and 
the quality of evidence in all studies in-
volved was assessed for each outcome ac-
cording to the following aspects: study de-
sign, heterogeneity and precision, indirect 
evidence, effect size, and publication bias. 
The assessment of the overall quality of ev-
idence across all endpoints was conducted 
using the lowest quality of evidence in the 
endpoints defined as “critical”. 
7. Vaccine efficacy
The STIKO working group defined and as-
sessed the following outcomes with regard 
to vaccine efficacy (see table 1): HZ inci-
dence (5 points), PHN (9 points), HZ-as-
sociated hospitalization (7 points), other 
complications (e. g. death [9 points]). Be-
cause the incidence of HZ increases with 
age, long-term protection provided by the 
vaccine is especially important. 
Vaccine efficacy (VE) is the percent-
age reduction of disease (e. g. HZ), or dis-
ease-related complications (e. g. PHN) in 
a vaccinated group of people compared 
to an unvaccinated group that is achieved 
under standardized conditions. The data 
used were collected in randomized clinical 
trials (RCTs). If no data could be extract-
ed from the RCTs included, data from co-
hort studies or the results of observational 
studies were also used (see section 8: vac-
cine efficacy, in particular for duration of 
vaccine protection). Two RCTs were in-
cluded in the systematic review on the ef-
ficacy of the live HZ vaccine; which are 
presented in more detail below [36, 37]. 
7.1. Shingles prevention study (SPS)
The SPS is the first randomized, dou-
ble-blind, placebo-controlled multicen-
tre study to confirm that the live zoster 
vaccine is effective in preventing HZ and 
PHN [36]. Patient recruitment was con-
ducted between November 1998 and Sep-
tember 2001 at 22 study centres in the 
USA at a ratio of 1:1 for the vaccine and 
placebo groups. It included 38,546 pa-
tients aged ≥60 years with a known medi-
cal history of chicken pox or with residen-
cy in the USA for ≥30 years (. Table 2). 
The follow-up was completed in April 
2004. 95% of the study participants were 
white, and 59% were men. The mean du-
ration of observation was 3.13 years (me-
dian: 3.12 years; range: 0.0–4.9). 95.3% of 
the subjects completed the study. 1% were 
lost to follow-up, and 4% died. Only 7% 
of the subjects (n = 2,595) were ≥80 years 
old, hence the statistical power for assess-
ing vaccine efficacy for this age group is 
limited.
Subcutaneous injections with either 
0.5 ml live attenuated zoster vaccine or 
placebo solution were administered. The 
appearance of the two solutions was dif-
ferent. The frozen vaccine was used in 
12 different concentrations ranging from 
18,700 to 60,000 PBE (median: 24,600 
PBE). More than 90% of those vaccinated 
received doses with <32,300 PBE (concen-
tration in the final HZ live vaccine product 
approved: 19,400 PBE).
A burden of illness (BOI) score was 
defined as the primary endpoint for vac-
cine efficacy; it consisted of the incidence 
of HZ and the duration and intensity of 
zoster pain. The individual severity of HZ 
pain and associated limitations in the daily 
routine were recorded on a scale of 0–10 
for an observation period of 6 months. 
PHN was selected as the secondary end-
point. PHN was defined as pain caused by 
HZ with a score of ≥3 on the pain scale, 
and which occurred or continued over 
certain periods of time (30, 60, 90, 120 and 
182 days) after the initial occurrence of the 
HZ rash. The follow-up for PHN was lim-
ited to 182 days after the start of the rash. 
The tertiary endpoint was defined as the 
occurrence of HZ. 
Skin rashes looking suspicious for HZ 
were examined by study investigators. 
HZ diagnoses were performed using PCR 
(93%) or virus culture (1%). If no materi-
al was available for a laboratory diagnosis, 
a 5-member expert team (6%) performed 
the HZ diagnosis based on the clinical 
picture. Participants who developed HZ 
in the first 30 days following vaccination 
were excluded from the analysis. 
VE against HZ was 51.3% (5.42 cas-
es/1,000 person-years (PY) in the inter-
vention group vs. 11.12 cases/1,000 PY 
in the placebo group; p < 0.001), and VE 
against PHN was 66.5% (0.46/1,000 PY 
vs. 1.38/1,000 PY). The vaccination sig-
nificantly reduced the RR of developing 
HZ (RR: 0.49 (95% CI 0.43–0.56) and lat-
er PHN (RR: 0.34 [95% CI 0.22–0.52]).
The VE against HZ declined with in-
creasing age (. Fig. 1) from 64% among 
60 to 69-year-olds to 41% among 70 to 
79-year-olds and 17% among those over 
the age of 80. The efficacy in the highest 
age group was not significant, as the con-
fidence interval (CI) of the RR included 1 
(RR: 0.83 [95% CI 0.54–1.27]). The analy-
sis in this group did not deliver statistical 
significant value due to the low number of 
participants. A total of approx. 9,000 sub-
jects aged ≥80 years would have been nec-
cessary for a statistically valid analysis. The 
VE against PHN among 60 to 69-year-
olds (65% [95% KI 22–84%]) and 70 to 
79-year-olds (74% [95% KI 50–86%]) was 
constant, but the results are highly impre-
cise (. Fig. 2). Taking the limitations giv-
en above into account no reliable proof of 
protection against PHN among ≥80-year-







Inclusion criteria Exclusion criteria
60–69 10,370 10,356 Age ≥60 (years) 
and  
medical history of 
varicella or  
≥30 years residency 
in the USA
Immunosuppression
of any type,  
recipient of blood 
products,  
acute illnesses such as 
influenza or urinary 
tract infection, recipi-





Total Ø 68.3 19,254 19,247
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olds (RR: 0.62 [95% CI 0.24–1.56]) could 
be proved. 
7.2. Zostavax efficacy and safety 
trial (ZEST)
The ZEST study is also a randomized, dou-
ble-blind, placebo-controlled multicentre 
study (ratio: 1:1) conducted to prove the 
efficacy of the live zoster vaccine in pro-
tecting from HZ at 105 study centres in 
North America and Europe between Oc-
tober 2007 and January 2010 [37]. 22,439 
subjects at the age of 50–59 years with a 
known medical history of chicken pox or 
≥30 years of residency in an area in which 
varicella was endemic were included (in-
tervention arm: 11,211 persons, place-
bo arm: 11,228 persons). 94.4% of the 
study participants were white, and 62% 
were women. The mean duration of ob-
servation was 1.3 years (range: 0 days to 2 
years). 94% of the subjects completed the 
study; 3% were lost to follow-up.
The subjects were administered either 
0.65 ml of the approved live HZ vaccine 
(19,400 PBE) or the identical quantity of 
a placebo solution subcutaneously. The 
primary endpoint of the study was the re-
duction in HZ incidence. Inclusion and 
exclusion criteria and the algorithm for 
diagnosing HZ were identical to those in 
the SPS study. The incidence of PHN was 
not investigated in this study.
The VE in protecting from HZ was 
69.8% (1.99 cases/1,000 PY in the vaccine 
arm vs. 6.57 cases/1,000 PY in the place-
bo arm; p < 0.001; . Fig. 1). The vaccina-
tion significantly reduced the relative risk 
of developing HZ (RR: 0.30 [95% CI 0.20–
0.46]). 
8. Duration of protection 
provided by the live attenuated 
HZ vaccine
In the RCTs described above, the ob-
servation period was too short to reach 
conclusions on the duration of protec-
tion from HZ or PHN [36, 37]. The sub-
jects from the SPS study continued to be 
observed in two subsequent studies with 
partial temporal overlap. But the blinding 
was lifted, the vaccine was offered to all 
placebo recipients, meaning the studies 
were conducted in part without a com-
parison group. Thus they no longer ful-
filled the quality criteria of an RCT. Un-
like vaccine efficacy under controlled 
conditions in a specifically defined pop-
ulation, vaccine effectiveness is deter-
mined in post-marketing studies under 
everyday conditions in the normal pop-
ulation. Hereinafter the results of retro-
spective cohort studies are shown in ad-
dition to the results of the SPS follow-up 
studies. The study results are especially 
important because they deliver informa-
tion on long-term protection after vacci-
nation. The data were extracted from the 
studies included in the same manner as 
described above.
8.1. Short-term persistence 
substudy (STPS)
The STPS study [38] is a continuation of 
the SPS study. It was initiated to investigate 
the duration of efficacy of the HZ vacci-
nation over a longer period of time. A to-
tal of 14,700 former SPS study participants 
(intervention arm: 7,320 persons, placebo 
arm: 6,950 persons) from 12 of the origi-
nal 24 SPS sites were included in the STPS 
study. The study was conducted from De-
cember 2004 to March 2006. Between the 
end of the SPS study and the start of the 
STPS study, ongoing surveillance of the 
participants was interrupted for a period 
of 15 months. The average age of partic-
Fig. 1 9 Efficacy of live 
attenuated HZ vaccine in 
preventing HZ in different 
age groups (≥50–59 years, 
≥60–69 years, ≥70–79 
years, ≥80 years; [36, 37])
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ipants was 73.3 years. The inclusion and 
exclusion criteria of the STPS were iden-
tical to those of the SPS, as were the con-
tact management, the three endpoints, 
case definition criteria (HZ and PHN), 
and diagnostic follow-up. Everyone who 
had received placebo in the SPS study was 
offered the live HZ vaccine; n = 6,194 sub-
jects from the placebo arm were given the 
vaccination during the STPS study. That 
led to more follow-up years per subject 
for the intervention arm than for the pla-
cebo arm (9,967 PY vs. 6,802 PY) in the 
STPS study.
Thus randomization and blinding were 
partially lifted in the STPS study, giving 
it more the character of an observation-
al study. 
The STPS study lasted between 3.3 and 
7.8 years after the initial vaccination in the 
SPS study. Aggregating the results of the 
SPS and STPS studies, findings on the pe-
riod of protection provided by the vacci-
nation are available for 0–7.8 years. 
The effectiveness of the HZ vaccina-
tion in protecting against HZ (. Fig. 3) 
decreased continuously over time from 
62% in post-vaccination year 1 to 49% in 
year 2, 47% in year 3, 45% in year 4, and 
43% in year 5. From year 6 onwards, no 
Fig. 2 9 Efficacy of live 
attenuated HZ vaccine in 
preventing postherpetic 
neuralgia in different age 
groups (≥60–69 years, 
≥70–79 years, ≥80 years; 
[36])
Fig. 3 8 Duration of efficacy and effectiveness of the live HZ vaccine in preventing HZ in persons aged ≥60 years, shown in 
years after vaccination (reference value: person-years); [38]. (The number of HZ cases and person-years in the follow-up of 
the SPS and STPS studies were aggregated to calculate the efficacy and effectiveness of the live HZ vaccine. 100% of the data 
were generated from the SPS study for the first 3 years, 97% from the SPS study and 3% from the STPS study for year 4, 16% 
from the SPS study and 84% from the STPS study for year 5, and 100% from the STPS study for years 6 and 7.)
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significant protection could be proved, but 
the number of observations was low, and 
the resulting confidence interval was very 
broad and included “1”.
The effectiveness of the HZ vaccina-
tion in protecting from PHN (. Fig. 4) 
decreased from 83% in the first post-vac-
cination year to 70% in year 2. From year 
3 onwards, no significant protection from 
PHN can be proved. 
8.2. Long-term persistence 
substudy (LTPS)
In the LTPS study, parts of the cohort of 
the SPS and STPS studies were followed 
up for a period of up to 11 years after vac-
cination [39]. The study was conducted 
from March 2006 to December 2010. The 
aim was to determine the level of protec-
tion in each year from years 7 to 11 after 
the vaccination. The methods used were 
identical to those in the preceding stud-
ies. Because no placebo group was avail-
able as a comparison, historical control 
data were used. Vaccinated subjects in 
the LTPS study were compared to sub-
jects of the same age from the SPS and 
STPS study, taking the increasing in-
cidence of HZ with advancing age into 
account. 6,867 subjects from the inter-
vention arm of the SPS study were in-
cluded in the LTPS study, and 25,250 
person-years recorded. The average age 
was 74.5 years. 
In the first year of observation, year 7 
after vaccination, VE in preventing HZ 
was found to be 46.0% (95% CI 28.4–60.2) 
in the LTPS study. The level of protection 
continued to fall over time, and in years 
9 to 11 after vaccination, no significant 
protection against HZ could be proved 
(. Fig. 5).
8.3. Retrospective cohort studies 
for the evaluation of the live HZ 
vaccine under everyday conditions 
in the post-marketing phase 
After the HZ vaccination was recom-
mended for adults aged ≥60 years in the 
US in 2006, a retrospective cohort study 
of members of the Kayser Permanente in 
southern California was conducted from 
January 2007 to December 2009 to evalu-
ate the live HZ vaccine [40]. Participants 
were immunocompetent adults aged ≥60 
years. At a ratio of 1:3, the incidence of HZ 
among 75,761 persons vaccinated at the 
age of ≥60 years was compared to that of 
227,283 non-vaccinated persons of com-
parable age (+/– 1 year). The mean fol-
low-up was 1.6 years for non-vaccinated 
persons and 1.7 years for vaccinated per-
sons. Over a period of 1.7 years, the VE in 
preventing HZ was 55% (95% CI 52–58) 
with no difference in efficacy according to 
age at time of vaccination, gender, race, or 
underlying diseases. The effectiveness in 
protecting from HZ-associated hospitali-
zation was 65% (95% CI: 49–67).
To examine the long-term protection 
provided by the vaccine, a follow-up study 
was initiated with the same study cohort, 
using the identical study design for a pe-
riod of 8 years [40, 41]. 176,078 subjects 
who received the vaccination between 
January 2007 and December 2014 at the 
age of ≥60 years were compared to 528,234 
non-vaccinated persons at a ratio of 1:3. 
The effectiveness of the vaccination de-
creased continuously over the observation 
period of 8 years after vaccination from 
69% (95% CI 66–71) in year 1 to 50% (95% 
CI46–53) in year 2, between 39% (95% CI 
34–44) and 33% (95% CI 23–42) in years 
3–6, 17% (95% CI 1–29) in year 7, and 4% 
(95% CI -24–26) in year 8. No significant 
vaccine protection was detectable in year 
8 after vaccination (. Fig. 6).
Fig. 4 8 Duration of efficacy and effectiveness of the live HZ vaccine in preventing PHN in persons aged ≥60 years, shown 
in years after vaccination (reference value: person-years); [38]. (The number of HZ cases and person-years in the follow-up of 
the SPS and STPS studies were aggregated to calculate the efficacy and effectiveness of the live HZ vaccine. 100% of the data 
were generated from the SPS study for the first 3 years, 97% from the SPS study and 3% from the STPS study for year 4, 16% 
from the SPS study and 84% from the STPS study for year 5, and 100% from the STPS study for years 6 and 7.)
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9. Conclusions on the efficacy 
and effectiveness of the HZ 
vaccination
The two RCTs identified show that the 
live HZ vaccine can prevent HZ in per-
sons aged ≥50 years [36, 37]. Because VE 
is strongly age-dependent and decreases 
with increasing age, pooled results over 
all age groups are not presented. VE is 
shown separately for every age group in 
the GRADE evidence profile. VE in pre-
venting HZ falls from 70% among 50 to 
59-year-olds to 41% among 70 to 79-year-
olds. VE among ≥80-year-olds is even 
lower, less than 20%. The CI of the point 
estimator is broad and includes the no-ef-
fect line. A precise statement is not possi-
ble due to the low number of participants 
in this age group. 
The vaccine can also prevent PHN 
after an HZ illness. Its efficacy is also 
age-dependent. VE is 65% among 60 
to 69-year-olds, and 74% among 70 to 
79-year-olds (with overlapping confi-
dence intervals). VE in preventing PHN 
is markedly lower among ≥80-year-olds, 
but a solid statement is not possible due 
to the low number of participants in this 
age group. The CI of the point estimator 
is broad and includes the no-effect line. 
No data are available to investigate the ef-
ficacy of protection from PHN among 50 
to 59-year-olds.
The RCTs included in the review do 
provide data on the efficacy of the vaccine 
in different age groups. However, it had 
been neglected to include enough partic-
ipants from the age group with the high-
est risk for HZ to be able to draw a clear 
conclusion on the protection by the vac-
cine provided at this age. The quality of 
evidence was therefore downgraded in the 
GRADE evidence profile due to the lack of 
precision (. Table 3).
Another reason for criticism is the 
fact that 12 vaccine batches were used in 
the STP study with varying levels of vi-
rus concentration (18,700–60,000 PBE). 
The approved product contains 19,400 
PBE. The quality of evidence was there-
fore downgraded due to indirect evidence 
with regard to the intervention. Overall, 
the quality of evidence was “low” to de-
termine that the live HZ vaccine is effec-
tive in preventing HZ and PHN in all age 
groups with regard to the outcomes in the 
evidence profile. The actual effect of the 
vaccine could vary substantially from the 
calculated effect estimates.
Both RCTs have a short observation 
period of 1.3 years (ZEST) and 3.1 years 
(SPS); for that reason it is not possible to 
provide data on the duration of vaccine 
protection. For this issue it was therefore 
necessary to combine the results from 
the SPS study and its follow-up studies 
(STPS and LTPS) (36, 38, 39) and to take 
into account the results of the post-mar-
keting study with members of the Kayser 
Permanente [41]. The results of the long-
term observations show, that the HZ vac-
cine provides only short term protection 
against HZ. These studies deliver data 
over a period of 8 to 11 years after vacci-
nation. Both studies show a marked reduc-
tion in VE in protecting against HZ from 
>60% to <50% in year 2 after vaccination 
(. Figs. 5 and 6). That is followed by a 
plateau phase of several years with slight-
ly declining protection rates: 40% to 50% 
in the SPS study and its follow-up studies, 
and 30% to 40% in the Kayser Permanente 
study. But unlike the Kayser Permanente 
study, the SPS/STPS/LTPS studies show 
widening confidence intervals for the 
point estimates from year to year, and the 
uncertainty of the point estimates increas-
es with time. In the Kayser Permanente 
study, the VE in year 7 after vaccination 
was 16.5%, and vaccine effectiveness from 
year 8 onwards was not demonstrated. 
The results of the SPS study show that 
the efficacy in protecting from PHN is 
brief and lasts only up to 2 years after vac-
cination. The live HZ vaccine provides 
protection from PHN by preventing HZ 
disease in the first place. If HZ disease can 
be prevented, no HZ-associated PHN can 
occur. If the vaccine induced protection 
from zoster wanes over time, its effective-
ness in preventing PHN is questionable. 
In summary, the live HZ vaccine does 
protect from HZ and PHN, but the results 
are unsatisfactory with regard to older age 
groups and with regard to the duration of 
protection. To provide protection at the 
age at which the risk of disease is greatest, 
the individual must be vaccinated as late as 
possible. But this is not very promising, as 
the vaccine does not demonstrate efficacy 
in older age groups. 
Fig. 5 8 Duration of efficacy and effectiveness of the live HZ vaccine in preventing HZ in persons aged 
≥60 years, shown in years after vaccination [36–38]. (The number of HZ cases and person-years in the 
follow-up of the SPS and STPS studies were aggregated to calculate the efficacy and effectiveness of 
the live HZ vaccine in years 4 and 5 after vaccination. 97% are from the SPS study and 3% from the 
STPS study for year 4, 16% from the SPS study and 84% from the STPS study for year 5, and 100% 
from the STPS study for years 6 and 7. The number of HZ cases and person-years in the follow-up of 
the STPS and LTPS studies were aggregated to calculate the efficacy and effectiveness of the live HZ 
vaccine in years 7 and 8 after vaccination. 31% of the data for year 7 are from the STPS study and 69% 
from the LTPS study; 8% of the data for year 8 are from the STPS study and 92% from the LTPS study.)
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10. Vaccine safety
The STIKO working group defined and 
evaluated the following endpoints as rel-
evant for the assessment of vaccine safe-
ty: non-severe local reactions (erythe-
ma, swelling, reactions at the point of 
injection; 3 points), severe local reactions 
(pain, 7 points), non-severe systemic re-
actions (fever; 4 points), severe system-
ic reactions and severe adverse events 
following immunization (SAE; 7 points; 
. Table 1).
A total of 5 RCTs were included to as-
sess the safety of the live HZ vaccine [36, 
37, 42–45]. They vary widely with re-
gard to their consideration of the rele-
vant endpoints and participant numbers. 
In . Table 4 the study duration, partici-
pant numbers, duration of follow-up, and 
the endpoints considered in the studies in-
cluded are listed.
10.1. Local reactions after 
vaccination with the live HZ vaccine
In the clinical safety studies, persons vac-
cinated with the HZ live attenuated vac-
cine reported local reactions at the injec-
tion site significantly more frequently than 
participants in the placebo group. Based 
on the analysis of the aggregated data, lo-
cal reactions at the injection site occurred 
in 60% of the subjects in the intervention 
group vs. 15% of the subjects in the pla-
cebo group. Swelling occurred in 26% vs. 
4.5%, erythema in 36% vs. 7%, and pain 
in 34% vs. 8% (. Fig. 7). The risk of local 
reactions was higher among participants 
aged 60–69 years (56.6%) than among 
subjects aged ≥70 years (39.2%; [45]). 
Most local reactions were minor and dis-
appeared within 4 days [36].
10.2. Systemic reactions after 
vaccination with the live HZ vaccine
Systemic reactions associated with the 
vaccination (headache, fatigue, pain in 
the extremities) were also more common 
in the intervention group than in the pla-
cebo group (RR 1.41; 95% CI 1.28–1.55) 
(. Fig. 8). Based on the analysis of the ag-
gregated data, systemic adverse side ef-
fects occurred in 6.6% of the intervention 
group and 4.7% of the placebo partici-
pants. Fever (>38.3 °C, oral) occurred at 
the same rate in both comparison groups. 
27 subjects (0.8%) in each of the interven-
tion and placebo group of the SPS sub-
study reported that they experienced fe-
ver after the vaccination.
10.3. Severe adverse events 
following vaccination
In the 5 clinical studies that examined the 
safety of the live HZ vaccine, nine out of 
a total of 65,175 participants experienced 
severe adverse events (SAE) which were 
considered to be caused by the live atten-
uated HZ vaccine or the placebo vacci-
nation. There were 5 cases in the verum 
group and 4 cases in the placebo group 
(see appendix (ESM_STIKO_Herpes_
zoster_2017.pdf)). The verum group cases 
included a 46-year-old woman with asth-
ma exacerbation, an 80-year-old man with 
a new case of polymyalgia rheumatica, one 
subject with an anaphylactic reaction 30 
minutes after the vaccination, one subject 
who developed uveitis, and one who de-
veloped sciatica. 
10.4. Varicella zoster and herpes 
zoster-like efflorescence, virus 
transmission after live HZ 
vaccination
As the results of the SPS study and its 
safety substudy showed, varicella-like ex-
anthem within 42 days after vaccination 
at the injection site occurred significantly 
more frequently in the intervention group 
(0.11%) than in the placebo group (0.04%; 
[36, 45]). It consisted of small, transient 
(5–7 days) vesicles that did not spread. 
Neither the wild-type virus nor the vac-
cine virus (Oka strain) could be verified 
in the lesions by culture or PCR. Varicel-
la-like exanthem occurred at the same rate 
on other parts of the body (0.1% vs. 0.1%; 
[36]). HZ-like efflorescence, i. e. vesicles 
that do not extend beyond the bounda-
ries of one dermatome, occurred more 
frequently within the first 42 days after 
vaccination in the placebo group than in 
the intervention group. HZ was diagnosed 
in 24 participants from the placebo group 
and 7 participants from the intervention 
group. Examination samples to verify the 
virus were present for all but one of those 
participants. The wild-type virus was veri-
fied in all of them; none of the sample con-
tained the vaccine virus (Oka strain, [45]). 
Transmission of the vaccine virus was not 
observed in the clinical studies. But find-
ings from the post-marketing phase of the 
varicella vaccines do hint that the vaccine 
Fig. 6 8 Duration of effectiveness of the live HZ vaccine in preventing HZ in persons aged ≥60 years, 
shown in years after vaccination [40, 41]
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virus may be transmitted to susceptible 
persons in rare cases by vaccinated per-
sons who developed varicella-like exan-
them after vaccination [46]. This risk of 
transmission is also plausible after admin-
istration of the live attenuated HZ vaccine. 
But the possibility of transmission of an at-
tenuated vaccine virus must be balanced 
with the risk of transmitting the VZ wild-
type virus to a susceptible person during 
a natural HZ illness.
10.5. Live HZ vaccine after prior HZ 
disease
The live attenuated HZ vaccine can also 
be administered to persons who already 
have a medical history of HZ disease. A 
crossover, placebo-controlled study of 101 
subjects aged ≥50 years showed that no se-
rious adverse side effects occurred with-
in 28 days after vaccination. Reactions at 
the injection site were considerably more 
frequent following the live attenuated 
HZ vaccine (45.9%) than the administra-
tion of placebo (4.2%). The percentage of 
subjects who experienced systemic ad-
verse side effects was similar in the ver-
um group (15.3%) and the placebo group 
(13.5%; [42]).
10.6. Summary assessment of the 
safety of the live HZ vaccine
Based on the results of clinical studies, the 
administration of the live HZ vaccine to 
persons at 50 years and older is safe and 
generally well tolerated. Although local 
Fig. 7 8 Forest plots of the relative risk (RR) of reactogenicity endpoints of the live HZ vaccine
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reactions at the injection site (swelling, 
pain, and redness) occurred more fre-
quently in vaccinated persons, they were 
mostly mild and transient (<4 days). The 
risk of local reactions is higher among 60 
to 69-year-olds than among older persons. 
The frequency of systemic adverse side ef-
fects was somewhat higher in the verum 
group than in the placebo group (6.3% vs. 
4.9%), most frequently headache and fa-
tigue. Fever (>38.3 °C) occurred with sim-
ilar frequency in the two groups, in less 
than 1% of the study participants. The in-
cidence of vaccine-associated SAEs was 
very low (<0.02%); there was no differ-
ence between the vaccination group and 
the placebo group. Varicella-like efflores-
cence at the injection site was rare overall, 
but occurred significantly more frequent-
ly in those who received the vaccine than 
in those who received placebo. No vacci-
nation virus could be verified in the vesi-
cles. Transmission of the vaccination virus 
was not observed in the clinical studies. 
The live attenuated HZ vaccine can also be 
administered to persons who have already 
had a zoster episode. The quality of evi-
dence for the endpoints assessed for safety 
is generally considered high (. Table 3). 
Only the quality of data on pain at the in-
jection site is seen as critical. It is consid-
ered objectionable that the confidence in-
tervals of the two studies included do not 
overlap, and that vaccines with differing 
virus concentration were used. 
11. Vaccination strategy
The primary aim of HZ vaccination was 
considered by STIKO in reducing disease 
burden caused by HZ in persons aged 50 
years and over. It was specified as follows, 
taking into account data on HZ epidemi-
ology in Germany, results of systematic 
reviews on vaccination efficacy, the peri-
od of protection provided by the vaccine 
in different age groups, and the results of 
the model and the health economics eval-
uation: In recommending a zoster vacci-
nation, the STIKO aims to substantially 
reduce the frequency and severity of HZ 
in older adults (≥70 years). The immuni-
ty of persons with existing VZV immu-
nity should be boosted with the HZ vac-
cine to reduce permanently the incidence 
of HZ, its complications, and the HZ se-
quela PHN.
12. Administration and 
contraindications
12.1. Dose and method of 
administration
The live attenuated HZ vaccine is admin-
istered after reconstitution of powder and 
solvent for injection. The vaccine can be 
injected subcutaneously or intramuscu-
larly as a single dose (0.65 ml), preferably 
Fig. 8 8 Forest plots of the relative risk (RR) of systemic and severe adverse reactions
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in the deltoid region. The vaccine should 
be administered in patients with severe 
thrombocytopenia or any coagulation dis-
order subcutaneously. A booster vaccina-
tion is not yet approved [47].
12.2. Coadministration with other 
vaccines
The live attenuated HZ vaccine can be 
administered concomitantly with inacti-
vated influenza vaccine as a separate in-
jection at different body sites. This was 
tested in an RCT in which 762 adults ≥ 50 
years received a single dose of live HZ vac-
cine, either concomitantly (n = 382) or not 
(n = 380), with an inactivated split influ-
enza vaccine [48]. The virus-specific im-
mune responses 4 weeks after vaccination 
were comparable for both vaccines, re-
gardless of whether the vaccines were ad-
ministered concomitantly or not.
The live HZ vaccine and the 23-valent 
pneumococcal polysaccharide vaccine 
Pneumovax® should not be administered 
concomitantly. Findings from one RCT 
show that simultaneous administration of 
the vaccines resulted in reduced immuno-
genicity of the live attenuated HZ vaccine. 
In a clinical study, 473 adults ≥ 60 years re-
ceived one dose of live HZ vaccine, either 
simultaneously (n = 237) or not (n = 236), 
with the 23-valent pneumococcal poly-
saccharide vaccine [49]. The VZV-spe-
cific immune responses after simultane-
ous administration, measured 4 weeks 
after vaccination, did not correspond to 
the VZV-specific immune responses after 
non-simultaneous administration. There-
fore, administration of the two vaccines 
should be considered to be separated by 
at least 4 weeks.
No data are available at this time on the 
simultaneous administration with other 
vaccines.
12.3. Contraindications
The live HZ vaccine is contraindicated for 
persons with a known hypersensitivity to 
one of the substances contained in the vac-
cine (e. g. neomycin).
It is also contraindicated under the 
following conditions or in the presence of 
one of the following diseases:
 5 Congenital or acquired immunode-
ficiency as a consequence of acute 
or chronic leukaemia, lymphoma, or 
any other disease of the bone marrow 
or the lymphatic system; immuno-
deficiency as a consequence of HIV/
AIDS; immunosuppressive therapy 
including high doses of corticoster-
oids
 5 Active, untreated tuberculosis
 5 Pregnancy
13. Health economic evaluation 
of HZ vaccination in Germany
13.1. Methods
An existing static Markov cohort model 
was developed for this analysis [50] and 
updated by implementing recent data 
specifically with regard to vaccine efficacy 
and duration of vaccine-induced protec-
tion. The model follows a simulated co-
hort of 1 million 50-year-olds to the end 
of their lives. It includes five conditions 
(health, death, HZ, PHN, and health af-
ter illnesses), and calculates with a cycle 
length of three months based on duration 
of HZ. The age at vaccination was var-
ied between 50, 60, and 70 years. In ad-
dition to the number needed to vaccinate 
(NNV) in order to prevent one HZ (PHN) 
case, the incremental cost-effectiveness ra-
tios (ICER) €/HZ case prevented (€/HZ) 
and €/quality adjusted life-year gained (€/
QALY) were calculated. All analyses were 
calculated from a societal perspective, i. e. 
including costs for disease-related sick 
leave. In addition to a base case analysis 
(vaccination at age 60, immunization costs 
of € 182 per person vaccinated, 35.3% vac-
cination coverage, and 3% annual dis-
count rate of costs and benefits), descrip-
tive univariate and probabilistic sensitivity 
analyses (PSA) were conducted in order 
to analyze the impact of input data uncer-
tainty. The model was developed using the 
programming language R.
13.2. Input data 
The input data for the model were partial-
ly updated and their impact on results in-
vestigated in sensitivity analyses. The data 
on epidemiology and the direct and indi-
rect treatment costs of HZ and PHN were 
taken from SHI billing data in Germany 
[1, 28]. The vaccination costs consist of 
€ 175 per vaccine dose (rote-liste.de, ef-
fective: 27 February 2017) and € 7 admin-
istration costs (assumption). The data on 
vaccine efficacy and vaccine-induced du-
ration of protection have already been de-
scribed above. Quality of life data to calcu-
late QALYs were taken from persons with 
HZ or PHN disease in Canada [51]. 
Fig. 9 8 Number of HZ cases with and without vaccination with the live HZ vaccine, NNV according to 
age at vaccination
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13.3. Results
In the base case, 6,161 HZ cases 
(NNV = 55), i. e. 2.34% of HZ cases, could 
be prevented with the live HZ vaccine 
(.  Fig. 9). A higher vaccination cover-
age of 60% (80%) could prevent 10,471 
(13,962) HZ cases. The lowest NNV is 51, 
and is achieved with vaccination at age 50. 
The NNV is 74 with vaccination at age 70. 
Depending on the age at vaccination, the 
relative reduction in HZ cases within one 
cohort ranges from 2.64% (age at vacci-
nation: 50) and 1.53% (age at vaccination: 
70). The NNVs to prevent one PHN case 
at ages 50, 60, and 70 years are 23,435, 
2,216, and 907, respectively.
Vaccination with the live HZ vac-
cine leads to ICERs of € 7,006/HZ and 
€ 88,357/QALY from societal perspective. 
Overall, vaccination in the base case leads 
to >€ 60 million in vaccination costs and 
a reduction in treatment costs of approx. 
€ 2.5 million. The most cost-effective age 
at vaccination appears to be 60 years. At a 
vaccination age of 50 and 70 years, the rel-
evant ICERs are € 104,845 and € 114,858/
QALY respectively. 
In sensitivity analyses it was shown 
that especially the vaccine-induced dura-
tion of protection, the price of the vaccine, 
and an assumed recurrence of HZ have 
the greatest impact on results. If theoreti-
cal lifelong vaccine protection is assumed, 
the ICER falls to € 9,242/QALY. Assum-
ing a period of protection of only 5 years 
leads to an ICER of € 151,909/QALY. If 
the immunization costs fall from € 182 
to € 82, the resulting ICER is € 37,665/
QALY. If they rise to € 282, the ICER is 
then € 139,049/QALY. If the model takes 
into account that a person can have HZ 
disease more than once, the ICER is then 
€ 70,933/QALY. A lower discount rate for 
effects or an assumed higher probabil-
ity of developing PHN also reduces the 
ICER. By contrast, the ICER rises con-
sistently if one takes the SHI (payer) per-
spective. In the PSA (10,000 Monte Car-
lo simulations), in which input data such 
as QALYs, treatment costs, epidemiology, 
and vaccine efficacy were varied within 
their confidence intervals based on like-
lihood distributions, 90% of the ICERs 
were between € 54,000 and € 107,000/
QALY. 
14. Conclusion and 
Recommendation
The German Standing Committee on Vac-
cination (STIKO) does not recommend 
the administration of the live attenuated 
herpes zoster (HZ) vaccine as a standard 
vaccination for the prevention of herpes 
zoster and its complications in the elderly. 
The STIKO based this decision on the re-
sults of a systematic review of the data on 
the safety and efficacy of the live attenu-
ated herpes zoster vaccine in accordance 
with its standard operating procedure 
(SOP). Available data on the epidemiolo-
gy of HZ in Germany and results of mod-
elling the epidemiological and health eco-
nomic effects of this vaccination were also 
taken into account.
An individual benefit-risk assessment 
may, however, lead to a different decision 
in individual patients.
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